JP2012526798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526798A5 JP2012526798A5 JP2012510440A JP2012510440A JP2012526798A5 JP 2012526798 A5 JP2012526798 A5 JP 2012526798A5 JP 2012510440 A JP2012510440 A JP 2012510440A JP 2012510440 A JP2012510440 A JP 2012510440A JP 2012526798 A5 JP2012526798 A5 JP 2012526798A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- agonist
- iop
- meca
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000000969 carrier Substances 0.000 claims 3
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical group C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 claims 1
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 claims 1
- 125000003853 4-amino-3-iodobenzyl group Chemical group [H]N([H])C1=C(I)C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000008784 Apnea Diseases 0.000 claims 1
- 206010002974 Apnoea Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (9)
- Ａ３ＡＲ作動薬がＩＯＰの被検者のＩＯＰの低下に有効であり有効成分として前記Ａ３ＡＲ作動薬および生理学的に許容される担体を含有する、前記被検者のＩＯＰを低下させる医薬組成物。
- 前記被検者がヒト被検者である、請求項１に記載に医薬組成物。
- 亢進したＩＯＰを有する被験者のＩＯＰを低下させるための、請求項１または２に記載の医薬組成物。
- 前記担体がＡ３ ＡＲ作動薬の経口投与に好適である、請求項１から３のいずれか１項に記載の組成物。
- １日２回の投与に好適な剤形で製剤された、請求項４記載の組成物。
- 前記担体が前記Ａ３ ＡＲ作動薬の局所投与に好適である、請求項１から５のいずれか１項に記載の組成物。
- 目に前記Ａ３ ＡＲ作動薬を投与するために製剤した、請求項６記載の組成物。
- 前記Ａ ３ ＡＲ作動薬がＮ６−２‐（４−アミノフェニル）エチルアデノシン（ＡＰＮＥＡ）、Ｎ６‐（４‐アミノ‐３‐ヨードベンジル）‐アデノシン‐５’‐Ｎ‐メチルウロンアミド（ＡＢ−ＭＥＣＡ）、Ｎ６‐（３‐ヨードベンジル）‐アデノシン‐５’‐Ｎ‐メチルウロンアミド（ＩＢ‐ＭＥＣＡ）および２−クロロ−Ｎ６−（３−ヨードベンジル）−アデノシン‐５’‐Ｎ‐メチルウロンアミド（ＣＩ‐ＩＢ−ＭＥＣＡ）からなる群から選択される、請求項１から７のいずれか１項に記載の組成物。
- 前記Ａ ３ ＡＲ作動薬がＩＢ−ＭＥＣＡである、請求項８記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL198787 | 2009-05-17 | ||
| IL19878709 | 2009-05-17 | ||
| PCT/IL2010/000393 WO2010134067A1 (en) | 2009-05-17 | 2010-05-16 | A3 adenosine receptor agonists for the reduction of intraocular pressure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526798A JP2012526798A (ja) | 2012-11-01 |
| JP2012526798A5 true JP2012526798A5 (ja) | 2013-07-04 |
| JP5849044B2 JP5849044B2 (ja) | 2016-01-27 |
Family
ID=42352183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510440A Expired - Fee Related JP5849044B2 (ja) | 2009-05-17 | 2010-05-16 | 眼圧低下のためのａ３アデノシン受容体作動薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8557790B2 (ja) |
| EP (1) | EP2432475A1 (ja) |
| JP (1) | JP5849044B2 (ja) |
| KR (1) | KR20120022919A (ja) |
| CN (1) | CN102427819A (ja) |
| AU (1) | AU2010250759B2 (ja) |
| CA (1) | CA2761499A1 (ja) |
| IL (1) | IL216114A (ja) |
| MX (1) | MX2011012229A (ja) |
| WO (1) | WO2010134067A1 (ja) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| AU7331094A (en) | 1993-07-13 | 1995-02-13 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | A3 adenosine receptor agonists |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| AU1399297A (en) | 1996-01-24 | 1997-08-20 | Sumitomo Chemical Company, Limited | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production |
| US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| WO1999006053A1 (en) | 1997-07-29 | 1999-02-11 | Medco Research, Inc. | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| US6329349B1 (en) | 1997-10-23 | 2001-12-11 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents |
| US6217896B1 (en) | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| AU2003282359A1 (en) * | 2002-11-19 | 2004-06-15 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
| BRPI0517639A (pt) * | 2004-11-08 | 2008-10-14 | Can Fite Biopharma Ltd | método para o tratamento de ressorção óssea acelerada, composição farmacêutica, e, uso de um agonista de a3ar |
| CN101083998A (zh) * | 2004-11-22 | 2007-12-05 | 王者制药研究发展有限公司 | 用腺苷a3受体激动剂强化治疗hif－1介导的病症 |
| WO2007002139A2 (en) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
| DK1983990T3 (da) * | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteriske A3-adenosin-receptormodulatorer |
| BRPI0621052A2 (pt) * | 2006-01-27 | 2012-07-17 | Can Fite Biopharma Ltd | uso de um agonista de receptor de adenosina a3 (a3ar) |
| US8153781B2 (en) * | 2007-06-29 | 2012-04-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily |
| EP3039030B1 (en) * | 2013-08-29 | 2018-09-19 | Yeda Research and Development Co. Ltd. | Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure |
-
2010
- 2010-05-16 JP JP2012510440A patent/JP5849044B2/ja not_active Expired - Fee Related
- 2010-05-16 EP EP10726312A patent/EP2432475A1/en not_active Withdrawn
- 2010-05-16 MX MX2011012229A patent/MX2011012229A/es not_active Application Discontinuation
- 2010-05-16 AU AU2010250759A patent/AU2010250759B2/en not_active Ceased
- 2010-05-16 KR KR1020117026858A patent/KR20120022919A/ko not_active Application Discontinuation
- 2010-05-16 US US13/320,715 patent/US8557790B2/en not_active Expired - Fee Related
- 2010-05-16 CA CA2761499A patent/CA2761499A1/en not_active Abandoned
- 2010-05-16 CN CN2010800212202A patent/CN102427819A/zh active Pending
- 2010-05-16 WO PCT/IL2010/000393 patent/WO2010134067A1/en active Application Filing
-
2011
- 2011-11-03 IL IL216114A patent/IL216114A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210205257A1 (en) | Methods and compositions for treating excessive sleepiness | |
| ES2370409T3 (es) | Forma de dosificación que contiene oxicodona y naloxona. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| MX2010006326A (es) | Comprimidos de desintegracion oral que comprenden difenhidramina. | |
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
| CA2622879A1 (en) | Use of a3 adenosine receptor agonist in osteoarthritis treatment | |
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013531041A5 (ja) | ||
| EA201190012A1 (ru) | Твердые лекарственные формы бендамустина | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| JP2006508953A5 (ja) | ||
| KR20190073365A (ko) | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 | |
| JP2013518124A5 (ja) | ||
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP2016525548A5 (ja) | ||
| JP2015514739A5 (ja) | ||
| JP2015522077A5 (ja) | ||
| JP2016505050A5 (ja) | ||
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| JP2009534367A5 (ja) |